Researchers are ushering in a new era of vaccine design that promises to be faster, more precise, and capable of tackling humanity’s most stubborn diseases.

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...